title: Bevacizumab: a new potential therapeutic option in sinusoidal obstruction syndrome.
authors.forename: Mehmet Ali Nahit
authors.initials: MA
authors.lastname: Şendur
authors.forename: Sercan
authors.initials: S
authors.lastname: Aksoy
authors.forename: Zafer
authors.initials: Z
authors.lastname: Arık
authors.forename: Şebnem
authors.initials: Ş
authors.lastname: Yaman
authors.forename: Nuriye Yıldırım
authors.initials: NY
authors.lastname: Özdemir
authors.forename: Dogan
authors.initials: D
authors.lastname: Uncu
authors.forename: Nurullah
authors.initials: N
authors.lastname: Zengin
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D006504:Hepatic Veno-Occlusive Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab